TY - JOUR
T1 - Impact of Patient Reminders on Papanicolaou Test Completion for High-Risk Patients Identified by a Clinical Decision Support System
AU - MacLaughlin, Kathy L.
AU - Kessler, Maya E.
AU - Komandur Elayavilli, Ravikumar
AU - Hickey, Branden C.
AU - Scheitel, Marianne R.
AU - Wagholikar, Kavishwar B.
AU - Liu, Hongfang
AU - Kremers, Walter K.
AU - Chaudhry, Rajeev
N1 - Funding Information:
The Agency for Healthcare Quality and Research supported this research through grant R21HS022911, ‘‘NLP-enabled decision support for cervical cancer screening and surveillance.’’ The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Department of Health and Human Services.
Publisher Copyright:
© Copyright 2018, Mary Ann Liebert, Inc. 2018.
PY - 2018/5
Y1 - 2018/5
N2 - Background: A clinical decision support system (CDSS) for cervical cancer screening identifies patients due for routine cervical cancer screening. Yet, high-risk patients who require more frequent screening or earlier follow-up to address past abnormal results are not identified. We aimed to assess the effect of a complex CDSS, incorporating national guidelines for high-risk patient screening and abnormal result management, its implementation to identify patients overdue for testing, and the outcome of sending a targeted recommendation for follow-up. Materials and Methods: At three primary care clinics affiliated with an academic medical center, a reminder recommending an appointment for Papanicolaou (Pap) testing or Pap and human papillomavirus cotesting was sent to high-risk women aged 18 through 65 years (intervention group) identified by CDSS as overdue for testing. Historical control patients, who did not receive a reminder, were identified by CDSS 1 year before the date when reminders were sent to the intervention group. Test completion rates were compared between the intervention and control groups through a generalized estimating equation extension. Results: Across the three sites, the average completion rate of recommended follow-up testing was significantly higher in the intervention group at 23.7% (61/257) than the completion rate at 3.3% (17/516) in the control group (p < 0.001). Conclusions: A CDSS with enhanced capabilities to identify high-risk women due for cervical cancer testing beyond routine screening intervals, with subsequent patient notification, has the potential to decrease cervical precancer and cancer by improving adherence to guideline-compliant follow-up and needed treatment.
AB - Background: A clinical decision support system (CDSS) for cervical cancer screening identifies patients due for routine cervical cancer screening. Yet, high-risk patients who require more frequent screening or earlier follow-up to address past abnormal results are not identified. We aimed to assess the effect of a complex CDSS, incorporating national guidelines for high-risk patient screening and abnormal result management, its implementation to identify patients overdue for testing, and the outcome of sending a targeted recommendation for follow-up. Materials and Methods: At three primary care clinics affiliated with an academic medical center, a reminder recommending an appointment for Papanicolaou (Pap) testing or Pap and human papillomavirus cotesting was sent to high-risk women aged 18 through 65 years (intervention group) identified by CDSS as overdue for testing. Historical control patients, who did not receive a reminder, were identified by CDSS 1 year before the date when reminders were sent to the intervention group. Test completion rates were compared between the intervention and control groups through a generalized estimating equation extension. Results: Across the three sites, the average completion rate of recommended follow-up testing was significantly higher in the intervention group at 23.7% (61/257) than the completion rate at 3.3% (17/516) in the control group (p < 0.001). Conclusions: A CDSS with enhanced capabilities to identify high-risk women due for cervical cancer testing beyond routine screening intervals, with subsequent patient notification, has the potential to decrease cervical precancer and cancer by improving adherence to guideline-compliant follow-up and needed treatment.
KW - Abnormal Pap management
KW - Cervical cancer prevention
KW - Clinical decision support
KW - Human papillomavirus
UR - http://www.scopus.com/inward/record.url?scp=85047434262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047434262&partnerID=8YFLogxK
U2 - 10.1089/jwh.2017.6667
DO - 10.1089/jwh.2017.6667
M3 - Article
C2 - 29297754
AN - SCOPUS:85047434262
SN - 1540-9996
VL - 27
SP - 569
EP - 574
JO - Journal of women's health (2002)
JF - Journal of women's health (2002)
IS - 5
ER -